Replimune (REPL) Income towards Parent Company (2017 - 2026)
Replimune (REPL) reported Income towards Parent Company of -$73.2 million for Q1 2026, up 1.34% on a YoY basis from -$72.2 million in Q1 2025, and down 3.14% sequentially from -$70.9 million in Q4 2025.
Replimune (REPL) Income towards Parent Company (2017 - 2026) Analysis & Trends
Replimune (REPL) has 10 years of Income towards Parent Company data on file, last reported at -$73.2 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company rose 1.34% year-over-year to -$73.2 million; the trailing twelve-month figure through Mar 2026 stood at -$395.8 million (down 60.01% YoY), and the FY2026 full-year result was -$313.9 million, down 26.91% from the prior year.
- Income towards Parent Company slipped to -$73.2 million in Q1 2026, from -$70.9 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$31.6 million in Q1 2022 to a low of -$128.7 million in Q2 2025.
- A 5-year average of -$62.6 million and a median of -$53.8 million in 2024 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company soared 51.52% in 2022 and slumped 139.39% in 2025, its largest moves.
- Tracing REPL's Income towards Parent Company over 5 years: stood at -$39.7 million in 2022, then slipped by 28.8% to -$51.1 million in 2023, then decreased by 29.77% to -$66.3 million in 2024, then decreased by 6.94% to -$70.9 million in 2025, then dropped by 3.14% to -$73.2 million in 2026.
- Business Quant data shows REPL's Income towards Parent Company at -$73.2 million in Q1 2026, -$70.9 million in Q4 2025, and -$122.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn |
| 10 | Replimune | 806.93 Mn | 806.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -73.17 Mn |
| Dec 31, 2025 | -70.94 Mn |
| Sep 30, 2025 | -122.92 Mn |
| Jun 30, 2025 | -128.72 Mn |
| Mar 31, 2025 | -74.16 Mn |
| Dec 31, 2024 | -66.34 Mn |
| Sep 30, 2024 | -53.06 Mn |
| Jun 30, 2024 | -53.77 Mn |
| Mar 31, 2024 | -55.08 Mn |
| Dec 31, 2023 | -51.12 Mn |
| Sep 30, 2023 | -60.04 Mn |
| Jun 30, 2023 | -49.56 Mn |
| Mar 31, 2023 | -49.25 Mn |
| Dec 31, 2022 | -39.69 Mn |
| Sep 30, 2022 | -43.10 Mn |
| Jun 30, 2022 | -42.25 Mn |
| Mar 31, 2022 | -31.62 Mn |
| Dec 31, 2021 | -81.86 Mn |
| Sep 30, 2021 | -82.05 Mn |
| Jun 30, 2021 | -80.79 Mn |